Development and Immunogenicity of a Prototype Multivalent Group B Streptococcus Bioconjugate Vaccine
Open Access
- 11 October 2021
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 7 (11), 3111-3123
- https://doi.org/10.1021/acsinfecdis.1c00415
Abstract
Group B Streptococcus (GBS) is a leading cause of neonatal infections and invasive diseases in nonpregnant adults worldwide. Developing a protective conjugate vaccine targeting the capsule of GBS has been pursued for more than 30 years; however, it has yet to yield a licensed product. In this study, we present a novel bioconjugation platform for producing a prototype multivalent GBS conjugate vaccine and its subsequent analytical and immunological characterizations. Using a glycoengineering strategy, we generated strains of Escherichia coli that recombinantly express the type Ia, type Ib, and type III GBS capsular polysaccharides. We then combined the type Ia-, Ib-, and III-capsule-expressing E. coli strains with an engineered Pseudomonas aeruginosa exotoxin A (EPA) carrier protein and the PglS oligosaccharyltransferase. Coexpression of a GBS capsule, the engineered EPA protein, and PglS enabled the covalent attachment of the target GBS capsule to an engineered serine residue on EPA, all within the periplasm of E. coli. GBS bioconjugates were purified, analytically characterized, and evaluated for immunogenicity and functional antibody responses. This proof-of-concept study signifies the first step in the development of a next-generation multivalent GBS bioconjugate vaccine, which was validated by the production of conjugates that are able to elicit functional antibodies directed against the GBS capsule.Keywords
Funding Information
- National Institute of Allergy and Infectious Diseases (R41AI142928)
This publication has 48 references indexed in Scilit:
- Development of a Fourfold Multiplexed Opsonophagocytosis Assay for Pneumococcal Antibodies against Additional Serotypes and Discovery of Serological Subtypes in Streptococcus pneumoniae Serotype 20Clinical and Vaccine Immunology, 2012
- Impact of the Conjugation Method on the Immunogenicity of Streptococcus pneumoniae Serotype 19F Polysaccharide in Conjugate VaccinesClinical and Vaccine Immunology, 2011
- Production of glycoprotein vaccines in Escherichia coliMicrobial Cell Factories, 2010
- Group B streptococcal conjugate vaccines elicit functional antibodies independent of strain O-acetylationVaccine, 2009
- Definition of the bacterial N-glycosylation site consensus sequenceThe EMBO Journal, 2006
- Use of Opsonophagocytosis for Serological Evaluation of Pneumococcal VaccinesClinical and Vaccine Immunology, 2006
- Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccineVaccine, 2003
- Safety and Immunogenicity of a Bivalent Group B Streptococcal Conjugate Vaccine for Serotypes II and IIIThe Journal of Infectious Diseases, 2003
- Four new derivatives of the broad-host-range cloning vector pBBR1MCS, carrying different antibiotic-resistance cassettesGene, 1995
- Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.JCI Insight, 1990